ArticleNature communications2022
Ultrafast one-minute electronic detection of SARS-CoV-2 infection by 3CL
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Selection of ssDNA aptamers targeting the serine protease SPSFQ of Acinetobacter baumannii and development of an electrochemical impedance spectroscopy-based ultrasensitive SPSFQ biosensor.Mikrochimica acta · 2026Article
- Universal Approach to Direct Spatiotemporal Dynamic In Situ Optical Visualization of On-Catalyst Water Splitting Electrochemical Processes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Saliva-based detection of SARS-CoV-2: a bibliometric analysis of global research.Molecular and cellular biochemistry · 2024Article
- Salivary diagnostics: opportunities and challenges.Theranostics · 2024Review
- Amplified fluorogenic immunoassay for early diagnosis and monitoring of Alzheimer's disease from tear fluid.Nature communications · 2023Article
- Real-time environmental surveillance of SARS-CoV-2 aerosols.Nature communications · 2023Article
- A Prototype Assay Multiplexing SARS-CoV-2 3CL-Protease and Angiotensin-Converting Enzyme 2 for Saliva-Based Diagnostics in COVID-19.Biosensors · 2023Article
- Emerging Landscape of SARS-CoV-2 Variants and Detection Technologies.Molecular diagnosis & therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its onset in December 2019, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, has caused over 6.5 million deaths worldwide as of October 2022. Attempts to curb viral transmission rely heavily on reliable testing to detect infections since a large number of transmissions are carried through asymptomatic individuals. Many available detection methods fall short in terms of reliability or point-of-care applicability. Here, we report an electrochemical approach targeting a viral proteolytic enzyme, 3CLpro, as a marker of active infection. We detect proteolytic activity directly from untreated saliva within one minute of sample incubation using a reduction-oxidation pH indicator. Importantly, clinical tests of saliva samples from 50 subjects show accurate detection of SARS-CoV-2, with high sensitivity and specificity, validated by PCR testing. These, coupled with our platform's ultrafast detection, simplicity, low cost and point-of-care compatibility, make it a promising method for the real-world SARS-CoV-2 mass-screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.